Last reviewed · How we verify
AO-128
AO-128 is a selective inhibitor of aldose reductase, an enzyme in the polyol pathway that converts glucose to sorbitol.
AO-128 is a selective inhibitor of aldose reductase, an enzyme in the polyol pathway that converts glucose to sorbitol. Used for Diabetic peripheral neuropathy, Diabetic complications (retinopathy, nephropathy).
At a glance
| Generic name | AO-128 |
|---|---|
| Also known as | Voglibose, BASEN |
| Sponsor | Takeda |
| Drug class | Aldose reductase inhibitor |
| Target | Aldose reductase |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
By inhibiting aldose reductase, AO-128 reduces the accumulation of sorbitol in tissues, which is thought to contribute to diabetic complications such as neuropathy, retinopathy, and nephropathy. This mechanism addresses the underlying metabolic dysfunction in diabetes-related microvascular complications.
Approved indications
- Diabetic peripheral neuropathy
- Diabetic complications (retinopathy, nephropathy)
Common side effects
- Gastrointestinal disturbances
- Headache
- Liver enzyme elevation
Key clinical trials
- Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"
- Postmarketing Clinical Study on AO-128 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |